Literature DB >> 11123280

Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.

J G Turner1, A L Rakhmilevich, L Burdelya, Z Neal, M Imboden, P M Sondel, H Yu.   

Abstract

We assessed the effect of the stimulatory anti-CD40 Ab on NK cell activation in vivo and the therapeutic potential of activated NK cells in tumor-bearing mice. Single-dose i.p. injection of the anti-CD40 Ab resulted in production of IL-12 and IFN-gamma in vivo, followed by a dramatic increase in NK cell cytolytic activity in PBLs. NK cell activation by anti-CD40 Ab was also observed in CD40 ligand knockout mice. Because NK cells express CD40 ligand but not CD40, our results suggest that NK activation is mediated by increased cytokine production upon CD40 ligation of APCs. Treatment of tumor-bearing mice with anti-CD40 Ab resulted in substantial antitumor and antimetastatic effects in three tumor models. Depletion of NK cells with anti-asialo GM1 Ab reduced or abrogated the observed antitumor effects in all the tested models. These results indicate that a stimulatory CD40 Ab indirectly activates NK cells, which can produce significant antitumor and antimetastatic effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123280     DOI: 10.4049/jimmunol.166.1.89

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Systemic treatment with anti-CD40 antibody stimulates Langerhans cell migration from the skin.

Authors:  S Jolles; J Christensen; M Holman; G B Klaus; A Ager
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

2.  Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.

Authors:  Meili Zhang; Wei Ju; Zhengsheng Yao; Ping Yu; Bih-Rong Wei; R Mark Simpson; Rebecca Waitz; Marcella Fassò; James P Allison; Thomas A Waldmann
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

3.  MUC16 suppresses human and murine innate immune responses.

Authors:  Mildred Felder; Arvinder Kapur; Alexander L Rakhmilevich; Xiaoyi Qu; Paul M Sondel; Stephen D Gillies; Joseph Connor; Manish S Patankar
Journal:  Gynecol Oncol       Date:  2019-01-06       Impact factor: 5.482

Review 4.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

Review 5.  Is cancer vaccination feasible at older age?

Authors:  Claudia Gravekamp; Arthee Jahangir
Journal:  Exp Gerontol       Date:  2014-02-06       Impact factor: 4.032

Review 6.  Aging and cancer vaccines.

Authors:  Claudia Gravekamp; Dinesh Chandra
Journal:  Crit Rev Oncog       Date:  2013

7.  Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Authors:  Kory L Alderson; Mitchell Luangrath; Megan M Elsenheimer; Stephen D Gillies; Fariba Navid; Alexander L Rakhmilevich; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-11-15       Impact factor: 6.968

8.  Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.

Authors:  Meili Zhang; Zhengsheng Yao; Sigrid Dubois; Wei Ju; Jürgen R Müller; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-21       Impact factor: 11.205

9.  Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Authors:  Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.